Targeting carbonic anhydrase to treat diabetic retinopathy: Emerging evidences and encouraging results

Journal Article · Fri Dec 18 00:00:00 EST 2009 · Biochemical and Biophysical Research Communications

DOI:https://doi.org/10.1016/J.BBRC.2009.10.031· OSTI ID:22199902

Weiwei, Zhang ^[1]; Hu, Renming ^[1]

---

1. Department of Endocrinology and Metabolism, HuaShan Hospital, Institute of Endocrinology and Diabetology, Shanghai Medical College, Fudan University, No. 12 Wulumuqi Road, Shanghai 200040 (China)

Diabetic retinopathy (DR) is the leading cause of vision loss among working-age populations in developed countries. Current treatment options are limited to tight glycemic, blood pressure control and destructive laser surgery. Carbonic anhydrases (CAs) are a group of enzymes involving in the rapid conversion of carbon dioxide to bicarbonate and protons. Emerging evidences reveal CA inhibitors hold the promise for the treatment of DR. This article summarizes encouraging results from clinical and animal studies, and reviews the possible mechanisms.

• OSTI ID: 22199902
• Journal Information: Biochemical and Biophysical Research Communications, Vol. 390, Issue 3; Other Information: Copyright (c) 2009 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0006-291X
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
ACID CARBONATES
ANIMALS
BLOOD PRESSURE
CALCIUM SULFIDES
CARBON DIOXIDE
CARBONIC ANHYDRASE
DEVELOPED COUNTRIES
REVIEWS
SURGERY
THERAPY